Teva Pharm nudges up earnings forecast, names new CFO
Reuters
Published Nov 07, 2019 08:14AM ET
Teva Pharm nudges up earnings forecast, names new CFO
JERUSALEM (Reuters) - Teva Pharmaceutical Industries (TA:TEVA) nudged up its full-year earnings guidance on Thursday, after reporting a drop in third-quarter profit that broadly met expectations.
The world's largest generic drugmaker earned 58 cents per diluted share excluding one-time items in the July-September period, down from 68 cents a year earlier.
It cited higher tax expenses and lower operating profit, which were partially offset by lower finance expenses.
Revenue fell 6% to $4.26 billion due to generic competition for its multiple sclerosis drug Copaxone and declines in sales in the United States, Russia and Japan, although it posted gains in some of its newly launched drugs.
Analysts had forecast Israel-based Teva (N:TEVA) would earn 59 cents a share ex-items on revenue of $4.24 billion, according to I/B/E/S data from Refinitiv.
Revenue in North America dipped 9% to $2.05 billion, with North American sales of Copaxone down 41% to $271 million. Its new migraine drug Ajovy had revenue of $25 million, while sales of Huntington's treatment Austedo rose to $105 million from $62 million.
Teva is looking to Ajovy and Austedo to boost revenue and help it pay down its huge debt load.
Chief Executive Kare Schultz said Teva remained on track to achieve a two-year restructuring target of $3 billion in spending reductions.
Teva said it had legal settlements of $468 million in the third quarter, mainly in connection with opioid cases in the United States.
Its debt load had fallen to $26.9 billion at the end of September from $28.7 billion three months earlier.
For 2019, the company raised its forecast for adjusted earnings per share (EPS) to $2.30-$2.50 from $2.20-$2.50 and revenue to $17.2-$17.4 billion from $17.0-$17.4 billion.
Analysts are forecasting EPS of $2.38 on revenue of $17.18 billion.
Teva also named Eli Kalif as its new chief financial officer effective Dec. 22.
Teva's shares were down 1.3% in afternoon trade in Tel Aviv.
Get The News You Want
Written By: Reuters
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.